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ABSTRACT
Background: The Food and Drug Administration, currently, is exploring
quantitative beneﬁt–risk methods to support regulatory decision-making.
A scientiﬁcally valid method for assessing patients’ beneﬁt–risk trade-off
preferences is needed to compare risks and beneﬁts in a common metric.
Objectives: The study aims to quantify the maximum acceptable risk
(MAR) of treatment-related adverse events (AEs) that women with
diarrhea-predominant irritable bowel syndrome (IBS) are willing to accept
in exchange for symptom relief.
Methods: Research design: A stated-choice survey was used to elicit trade-
off preferences among constructed treatment proﬁles, each deﬁned by
symptom severity and treatment-related AEs. Symptom attributes included
frequency of abdominal pain and discomfort, frequency of diarrhea, and
frequency of urgency. AE attributes included frequency of mild-to-
moderate constipation and the risk of four possible serious AEs. Subjects:
A Web-enabled survey was administered to 589 female US residents at
least 18 years of age with a self-reported diagnosis of diarrhea-
predominant IBS.
Measures: Preference weights and MAR were estimated using mixed-logit
methods.
Results: Subjects were willing to accept higher risks of serious AEs in
return for treatments offering better symptom control. For an improve-
ment from the lowest to the highest of four beneﬁt levels, subjects were
willing to tolerate a 2.65% increase in impacted-bowel risk, but only a
1.34% increase in perforated-bowel risk.
Conclusions: Variation in MARs across AE types is consistent with the
relative seriousness of the AEs. Stated-preference methods offer a scien-
tiﬁcally valid approach to quantifying beneﬁt–risk trade-off preferences
that can be used to inform regulatory decision-making.
Keywords: beneﬁt–risk analysis, conjoint analysis, incremental net ben-
eﬁts, irritable bowel syndrome, maximum acceptable risk.
Introduction
Several recent and well-publicized events involving withdrawals
of drugs from the US market have highlighted the problem of
balancing beneﬁts and risks [1]. In all these cases, interventions
offering potentially signiﬁcant therapeutic beneﬁts were found to
carry increased risks of serious and, possibly, life-threatening
adverse events (AEs). Decisions to halt the development or mar-
keting of such therapies clearly require balancing beneﬁts and
risks. Despite the importance of establishing consistent and prin-
cipled criteria for determining when beneﬁts outweigh risks,
experts have provided surprisingly little guidance to help
decision-makers evaluate such trade-offs.
A review of past examples of product withdrawals and risk-
management decisions in different countries reported that deci-
sions, often, are inconsistent and are based on very limited
scientiﬁc evidence beyond the original clinical trial data relating
to safety and efﬁcacy [2]. In addition, the recent Institute of
Medicine report, The Future of Drug Safety, a study requested by
the US Food and Drug Administration (FDA) to address recog-
nized shortcomings of the US drug-safety system, noted that “in
both the preapproval and the postmarketing setting, the risk-
beneﬁt analysis that currently goes into regulatory decisions
appears to be ad hoc, informal, and qualitative” [3]. The FDA
Amendments Act of 2007 called on the agency to collaborate
with public and private entities to improve the quality of beneﬁt–
risk analysis (H.R. 3580 [Public Law 110-85] §904).
Regulatory agencies do not require quantifying or even
formal consideration of the values of patients, physicians, or
other stakeholders in risk evaluations. The values and risk toler-
ance of patients with a particular condition may be presented to
advisory panels and policymakers either individually or through
advocacy organizations; however, there is no transparent or con-
sistent mechanism currently in place for quantifying systemati-
cally the values and risk tolerance of these ultimate stakeholders.
The case of alosetron illustrates the need for quantitative,
preference-based, beneﬁt–risk analysis. Alosetron was approved
for marketing by the FDA in February 2000. The approved
indication was for diarrhea-predominant irritable bowel syn-
drome (IBS) in women only. Although clinical trials demon-
strated that alosetron provided relief of abdominal pain and
discomfort, improvement in urgency, and decreased frequency of
diarrhea [4], safety signals indicated the possibility of serious
gastrointestinal AEs. The most serious risk of concern associated
with alosetron was the possibility that women with IBS taking
the drug would develop a perforated bowel requiring surgery. As
a result, alosetron was withdrawn from the market 9 months
after launch. In June 2002, in response to pressure from patient
organizations and reanalysis of data, the FDA reapproved the
drug for restricted use in a more targeted indication under a
risk-management program.
Understanding the value that women with IBS place on treat-
ment outcomes and their willingness to accept risks in return
for treatment beneﬁts can help inform future regulatory and
risk-management decision-making. In this study, we employed
well-established stated-choice (SC) methods (also known as
choice-format conjoint analysis or discrete-choice experiments)
to quantify the maximum acceptable risk (MAR) of treatment-
related AEs that women with diarrhea-predominant IBS are
willing to accept in exchange for symptom relief. In a related
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study published in this journal, these estimates were used to
construct preference weights, which were used in an event-
simulation model, to estimate the incremental net beneﬁts of
alosetron [5].
Methods
SC Methods
In an SC survey, a sample of patients, physicians, or caregivers
are asked to choose between treatment options where attribute
levels are varied across options and across choice tasks [6–8]. SC
methods yield quantitative estimates of trade-offs subjects are
willing to make among treatment attributes and yield estimates
of relative preference weights. These weights can be used to
populate models in lieu of conventional health-state utilities or to
scale therapeutic improvements in terms of one of the attributes,
such as money, risk, or time [9,10].
Survey Development
Treatment-related beneﬁts and risks were identiﬁed from a
review of the literature, consultations with medical experts
involved in IBS clinical trials, and interviews with women with
diarrhea-predominant IBS. In each treatment-choice question in
the survey, symptom attributes included 1) frequency of abdomi-
nal pain and discomfort; 2) frequency of diarrhea; and 3) fre-
quency of feelings of urgency. AE attributes included 1)
frequency of mild-to-moderate constipation and 2) risks of four
additional AEs—three of them serious. AE risks included prob-
abilities of moderate colitis, impacted bowel, severe colitis, and
perforated bowel (Table 1). Probabilities of experiencing each AE
ranged from 0% to 1%. Pretests were conducted using in-person
interviews with eight women between 29 years and 60 years of
age with a self-reported diagnosis of diarrhea-predominant IBS.
Figure 1 provides an example of the SC question format. We
employed a commonly used algorithm to construct a statistically
efﬁcient experimental design resulting in 48 treatment-choice
pairs [11–15]. We implemented an extension of Zwerina et al.’s
algorithm that searches for maximum D-efﬁciency, subject to no
dominated pairs, minimal overlaps, and best level balance
[13,15]. The design with the highest D-score achieved an accept-
able level of statistical efﬁciency for our sample size, as indicated
by conﬁdence intervals on the parameter estimates. Kanninen
shows that prior information on parameter values can be used to
improve design efﬁciency [14]. We did not have any information
with which to specify priors for the parameters other than
natural ordering, which we used in the search algorithm to screen
out dominated pairs.
To reduce cognitive and time burden, treatment-choice ques-
tions were blocked into six sets of eight questions, and each
subject was randomly assigned to one of the six sets. The ﬁnal
survey instrument also included questions regarding each sub-
ject’s personal characteristics (e.g., age and education) and expe-
rience with IBS and IBS treatments. The survey was approved by
the Research Triangle Institute’s Ofﬁce of Research Protection
and Ethics.
Survey Sample
The Web-enabled survey was programed by Ipsos Observer, an
international survey-research ﬁrm [16], and administered to
female members of the Ipsos Online Access Panel. All subjects
were required to have had a physician diagnosis of diarrhea-
predominant IBS (self-reported) and to be US residents, at least
18 years of age. Study subjects were entered into a drawing to
win one of the ﬁve $100 cash prizes offered as an incentive for
their participation.
Statistical Analysis
We used multivariate, random-parameters panel-logit regression
to estimate preference parameters for each attribute level [17].
Explanatory variables in the random-parameters logit model
included all attribute levels listed in Table 1. All statistical analy-
ses were conducted using GAUSS 7.0 (Aptech Systems, Inc.,
Black Diamond, WA) [18].
The parameter estimates from SC models are preference
weights that indicate the relative strength of subjects’ preference
for each attribute level. Attribute levels were effects coded. The
preference weight for the omitted category is the negative sum of
the included-category parameters [19]. Thus, zero is the mean
effect for each attribute, and positive and negative preference
weights are interpreted relative to the mean effect of the attribute
on treatment choice.
MAR Calculations
Estimated preference parameters were used to calculate the mean
MAR for each serious AE—impacted bowel, severe colitis, and
Table 1 Irritable bowel syndrome (IBS) treatment attributes and levels
Treatment attribute Levels
Frequency of abdominal
pain and discomfort
No IBS pain and discomfort
IBS pain and discomfort for 1 week a month
IBS pain and discomfort for 2 weeks a month
IBS pain and discomfort for 3 weeks a month
IBS pain and discomfort for 4 weeks a month
Diarrhea frequency No diarrhea
Diarrhea 2 times a day
Diarrhea 4 times a day
Diarrhea more than 4 times a day
Urgency frequency No urgency
Urgency 2 days a week
Urgency 5 days a week
Urgency 7 days a week
Frequency of mild-to-
moderate constipation
No constipation
Constipation 1 week a month
Constipation 2 weeks a month
Constipation 3 weeks a month
Constipation 4 weeks a month
Chance of serious
adverse event
No chance of severe adverse event
1 person out of 1000 (0.1%) will have moderate
colitis requiring doctor’s care
5 people out of 1000 (0.5%) will have moderate
colitis requiring doctor’s care
10 people out of 1000 (1%) will have moderate
colitis requiring doctor’s care
1 person out of 1000 (0.1%) will have an
impacted bowel requiring doctor’s care
5 people out of 1000 (0.5%) will have an
impacted bowel requiring doctor’s care
10 people out of 1000 (1%) will have an
impacted bowel requiring doctor’s care
1 person out of 1000 (0.1%) will have severe
colitis requiring hospitalization
5 people out of 1000 (0.5%) will have severe
colitis requiring hospitalization
10 people out of 1000 (1%) will have severe
colitis requiring hospitalization
1 person out of 1000 (0.1%) will have a
perforated bowel requiring surgery
5 people out of 1000 (0.5%) will have a
perforated bowel requiring surgery
10 people out of 1000 (1%) will have a
perforated bowel requiring surgery
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perforated bowel. MAR is deﬁned as the maximum probability
of experiencing a treatment-related AE that subjects are, on
average, willing to accept to obtain a given level of symptom
improvement.
Specifying all attribute levels as discrete variables, the MAR
for AE i for an improvement in symptoms can be deﬁned as:
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where Sj0 is the estimated preference parameter for the initial set
of symptom levels, and Sj1 is the estimated preference parameter
for the improved set of symptom levels. We calculate the amount
of risk that exactly offsets the beneﬁt of improved symptoms. Rki
is the preference parameter for risk type i. If the offsetting value
lies between Rmi j and Rm
i
j +1, we solve for fraction fij to linearly
interpolate between the two discrete risk levels. Finally, we cal-
culate MAR as r f rmi ij mij j+ × +1, where rm
i is the AE probability
corresponding to preference parameter Rmi . This calculation is
directly analogous to estimating willingness to pay with a non-
linear cost function.
Results
Survey Population
Of all the individuals who were eligible, 589 individuals com-
pleted the online questionnaire. Of these 589 individuals, 13 did
not vary their choices across the trade-off questions (i.e., they
picked Medicine A or Medicine B in every choice question).
Exclusion of these subjects resulted in an analysis sample of 576
patients. Table 2 summarizes the personal characteristics and IBS
experience of these subjects. The demographic characteristics of
the subjects were similar to those of the women enrolled in two
trials of alosetron efﬁcacy and safety [20,21].
Preference Weights
Preference weights for the attribute levels are presented in
Figure 2 (The effects-coded, random-parameters estimates used
to derive preference weights are available from the authors).
Estimates are naturally ordered except for no AE risk and 0.1%
chance of moderate colitis. This difference was statistically insig-
niﬁcant. The treatment attribute with the highest relative impor-
tance weight was perforated-bowel risk, followed by severe-
colitis risk, frequency of abdominal pain, and diarrhea,
respectively. The least important attribute was the risk of mod-
erate colitis. The relative importances of the two most important
attributes were not statistically signiﬁcantly different from each
other, but these two attributes were signiﬁcantly more important
than the other attributes (P < 0.05).
MAR
MARs for the three serious AEs for each of the four deﬁned levels
of beneﬁt are presented in Table 3 (MARs for other combinations
of symptom outcomes are available from the authors by request).
MAR estimates ranged from 0.03% to 2.83%. As expected,
subjects in our sample were willing to accept higher levels of risk
in return for greater improvements in symptoms. For each level
of treatment beneﬁt, MAR estimates were highest for impacted
bowel and lowest for perforated bowel, indicating that subjects
Feature Medicine A Medicine B
2 weeks of pain and 
discomfort per month
4 weeks of pain and 
discomfort per month
Feeling of urgency 
2 days a week
Feeling of urgency 
5 days a week
2 weeks of constipation 
per month
3 weeks of constipation 
per month
No chance of severe side effect
Which medicine do you prefer?
10 people out of 1,000  (1%)  
will have a perforated bowel 
requiring surgery 
Diarrhea 4 times a day Diarrhea 2 times a day
Frequency of pain and 
discomfort
Frequency of diarrhea
Feeling of urgency
Mild to moderate 
constipation
Chance of severe side 
effect
 ❍ Medicine A  ❍ Medicine B
Figure 1 Example of stated-preference trade-off question.
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had greater tolerance for the relatively less serious risk of
impacted bowel than for the much more serious risk of perfo-
rated bowel.
We compared the risk tolerance of subjects who reported
serious IBS symptoms (serious pain or discomfort, urgency or
soiling of clothes, or IBS symptoms that impact their daily activi-
ties) or who took or had taken prescription medications to treat
IBS with subjects who did not have these characteristics. Patients
with more serious symptoms have higher MARs than patients
who had less serious symptoms. For example, for full beneﬁt,
subjects with more serious symptoms are willing to accept
3.76% and 1.57% risks of impacted and perforated bowel,
respectively. In contrast, subjects with less serious symptoms
were willing to accept only 1.64% and 1.19% risks (P < 0.01 for
both comparisons).
Discussion
As expected, women’s choices indicated a systematic preference
for treatments that provide larger reductions in symptom fre-
quency. In many instances, preferences for symptom relief out-
weighed concerns about AE risks. For example, the estimated
preference weight for no abdominal pain and discomfort is
greater than the estimated preference weight for no risk of
serious AEs, indicating that relief of abdominal pain and discom-
fort was more important to these women than is eliminating the
AE risks.
Variation in the MAR measure of risk tolerance was consis-
tent with the relative seriousness of the AEs. For example, for a
treatment offering moderate symptom improvement relative to
severe symptoms, MAR for impacted bowel was 1.53%, whereas
MAR for perforated bowel was only 0.86%. The estimated
MARs for clinically meaningful symptom improvements are sub-
stantially above their estimated rates of occurrence across each of
the serious AEs of interest [22].
Most importantly, estimating preference weights for
treatment outcomes and risks, and quantifying the relative
importance of each attribute offer a solution to the problem in
beneﬁt–risk analysis that risks and beneﬁts are measured in non-
comparable units. In a companion article, these preference
weights are used in the ﬁrst incremental net beneﬁt analysis to use
such patient data to compare treatment beneﬁts and risks [5].
One inherent limitation of this methodology is that SC ques-
tions ask subjects to evaluate hypothetical treatments. Thus,
differences can arise between stated and actual choices. In the
present study, potential hypothetical bias is minimized by offer-
ing alternates that mimic real-world trade-offs as closely as
possible.
Subjects enrolled through the Ipsos Observer were not
screened to conﬁrm their reported IBS diagnosis. We consider it
is unlikely that people who do not have IBS completed the survey
because no personal gain was associated with participation in the
survey, other than a chance to win one of the ﬁve $100 cash
incentives. In addition, participation required a commitment of
approximately 30 minutes to complete the survey, and the SC
trade-off tasks are mentally taxing exercises that are unlikely to
attract a casual respondent.
Health status is based on patients’ own report of a physician
diagnosis of IBS. We have no independent veriﬁcation of that
diagnosis. Nevertheless, we followed up the self-report with
questions on type and severity of symptoms—abdominal pain
and discomfort, feeling of urgency or soiling clothes, and inabil-
ity to lead a normal home or work life because of the need to be
near a bathroom. About 80% of the subjects indicated one or
more of these symptoms were “frequent,” and 75% judged the
severity to be moderate or severe.
As indicated, this study provided weights for a separate mod-
eling study to estimate incremental net beneﬁts. We thus were
constrained to obtain weights that matched the end points in
clinical-trial data. Rates for each outcome are reported, and thus
modeled, independently. For example, subjects sometimes evalu-
ated outcome proﬁles that included both IBS-related diarrhea
and medication-induced constipation in the same week. The
effect of a given diarrhea frequency might be different, depending
on the combination of diarrhea days and constipation days in
that week. This interaction effect is not reﬂected in our impor-
tance estimates for these end points. Conventional health-state
utility weights widely used in cost-effectiveness analyses also
treat outcomes as independent and are subject to the same limi-
tation. One could argue that models and importance weights
should account for interactions among outcomes, but they do not
because the data on which models are based generally do not
provide the necessary information to model such interactions. An
important topic for future research would be to relax the inde-
pendence requirement in both the model and the preference
weights to evaluate the signiﬁcance of this requirement.
Patients’ perspectives on balancing beneﬁts and risks may be
useful in informing both treatment and regulatory decisions.
Because risks, often, are inseparable from efﬁcacy, one cannot
easily deﬁne what level of risk is intolerable without reference to
the beneﬁts associated with increased risk. SC studies such as this
one may help decision-makers understand the levels of risks that
patients are willing to accept in return for therapeutic beneﬁts.
Quantitative estimates of preferences for combinations of risks
and beneﬁts developed using rigorous and theoretically sound
techniques, such as those used in this study, may assist regulatory
Table 2 Patient demographic characteristics and irritable bowel syn-
drome (IBS) experience
Characteristic
Sample
(N = 576)
Age, mean (SD), year 47 (12)
Race/ethnicity, n (%)
White 546 (95)
Black/African American 6 (1)
Native American or Alaska Native 7 (1)
Other 17 (3)
Employment status, n (%)
Employed for wages full time 170 (30)
Employed for wages part-time 76 (13)
Self-employed 33 (6)
Homemaker 89 (15)
Student 13 (2)
Retired 71 (12)
With disability/unable to work 100 (17)
Unemployed, but looking for work 24 (4)
Highest level of education, n (%)
High school or equivalent 80 (14)
Trade school 27 (5)
Some college but no degree 222 (39)
Associate’s degree 92 (16)
Bachelor’s/college degree or higher 155 (27)
How long since diagnosed, mean (SD), year 10 (9)
Severity of IBS symptoms
Mild 26 (5)
Mild to moderate 117 (20)
Moderate 186 (32)
Moderate to severe 214 (37)
Severe 33 (6)
Symptoms experience with IBS, n (%)
Frequent and severe abdominal pain and discomfort 462 (80)
Frequent feeling of urgency 441 (77)
Limitations on daily activities 365 (63)
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authorities in evaluating new treatments, making the rationale
for decisions more transparent and helping physicians and
patients make better-informed choices among treatments.
Source of ﬁnancial support: This study was funded by GlaxoSmithKline.
The views expressed herein do not necessarily reﬂect those of the sponsor.
As the supervisor for the study, F. Reed Johnson had full access to all of the
data in the study and takes responsibility for the integrity of the data and
the accuracy of the data analysis.
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